Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 9:30 a.m. ET. Murdo Gordon, Amgen's executive vice president of Global Commercial Operations, will lead the presentation, which will be webcast for the media, investors, and the public. The event highlights Amgen's commitment to innovation in biotechnology and advanced human genetics. The webcast will be available for replay for 90 days post-event on Amgen's official website.
Amgen announced positive topline results from its Phase 2 OCEAN(a)-DOSE study, revealing that olpasiran, an investigational treatment, successfully reduced Lipoprotein(a) levels by over 90% in many patients at weeks 36 and 48. The trial involved 281 adult patients with elevated Lp(a) levels and atherosclerotic cardiovascular disease. No new safety issues were reported, and the results are expected to be presented at a future medical congress. These findings could provide new options for patients with limited treatment alternatives for elevated Lp(a).
Amgen will present findings from its oncology portfolio at the ASCO Annual Meeting from June 3-7, 2022. Key updates include the results of the PARADIGM Phase 3 trial comparing Vectibix® with Avastin® for RAS wild-type metastatic colorectal cancer. Additionally, new data on LUMAKRAS® (sotorasib) from the CodeBreaK 100 study highlights resistance mechanisms in KRAS G12C-mutated cancers. This reflects Amgen's commitment to enhancing treatments for challenging cancers. The presentations will cover a range of investigational therapies aimed at improving patient outcomes.
Amgen has launched the 'Double Take' campaign in collaboration with pop icon Lance Bass to raise awareness about psoriatic arthritis. The campaign aims to educate individuals on recognizing early symptoms of the condition, which affects about one million Americans and often goes unnoticed. Bass shares his personal journey of diagnosis and emphasizes the importance of early intervention. The Otezla (apremilast), used for treatment, is highlighted along with its potential side effects, including diarrhea and nausea.
Amgen (NASDAQ:AMGN) will present at the 2022 Bank of America Healthcare Conference on May 11, 2022, at 12:20 p.m. ET. Key executives, including David M. Reese and Peter H. Griffith, will discuss company developments. The presentation will be available via webcast, accessible to investors and the public, and archived for 90 days. Amgen, a leading biotechnology firm, focuses on innovative treatments for serious illnesses and is recognized for its contributions in healthcare, sustainability, and corporate culture.
Amgen (NASDAQ:AMGN) has released its 2021 Environmental, Social & Governance (ESG) report, outlining its commitment to public health and sustainability. The report highlights four key areas: Healthy People, providing $2.2 billion in free medicines; Healthy Society, impacting 27 million through no-cost science education; Healthy Planet, pursuing carbon neutrality by 2027; and A Healthy Amgen, integrating ESG goals into business practices. Recognized by various organizations, Amgen continues to emphasize its role in improving health outcomes and addressing societal challenges.
Amgen reported Q1 2022 total revenues of $6.2 billion, a 6% increase from Q1 2021, driven by 2% growth in product sales and enhanced COVID-19 collaboration revenue. GAAP EPS decreased by 5% to $2.68, while non-GAAP EPS increased by 15% to $4.25. Operating income grew 17% to $2.5 billion, improving the operating margin to 43.6%. Amgen reaffirmed total revenue guidance for 2022 at $25.4-$26.5 billion while adjusting GAAP EPS guidance to $12.53-$13.58. Challenges include IRS tax disputes potentially increasing liabilities by $7.1 billion.
Amgen has released positive results from two open-label extension studies evaluating the long-term safety and tolerability of Repatha (evolocumab) in over 6,600 patients. These studies, following the Phase 3 FOURIER trial, show that Repatha is safe for extended use, with no new safety issues reported over five years. More than 85% of patients achieved LDL-C levels below 40 mg/dL. Amgen emphasizes Repatha's sustained effectiveness in lowering LDL-C in patients with atherosclerotic cardiovascular disease, reinforcing its position as a leader in PCSK9 inhibitors.
Amgen (NASDAQ:AMGN) plans to announce its first quarter financial results on April 27, 2022, after U.S. market close, followed by a conference call at 2:00 p.m. PT. The call will include CEO Robert A. Bradway and senior management, and will be accessible via live audio broadcast online. The conference will discuss Amgen's ongoing commitment to developing innovative therapies and its strong market position as a leading biotechnology company since 1980. More information and the webcast can be found on Amgen's website.
Amgen announced preliminary results from a Phase 3 study of ABP 654, a biosimilar candidate to STELARA (ustekinumab), for treating moderate to severe plaque psoriasis. The primary efficacy analysis showed no clinically meaningful differences between ABP 654 and STELARA, with a mean difference of 0.14 in percentage improvement in psoriasis area severity index (PASI) from baseline to week 12. The safety profile was comparable between both treatments. Amgen aims to expand its biosimilars portfolio, which includes 11 candidates.